<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935517</url>
  </required_header>
  <id_info>
    <org_study_id>AGTC-CNGA3-002</org_study_id>
    <nct_id>NCT02935517</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia</brief_title>
  <official_title>A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Genetic Technologies Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Genetic Technologies Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
      AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia
      caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the
      secondary study endpoint will be efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
      AGTC-402 administered to one eye by subretinal injection in individuals with achromatopsia
      caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the
      secondary study endpoint will be efficacy.

      Subjects will be enrolled sequentially in four groups. Subjects in Groups 1, 2 and 3 will be
      between 18 and 55 years of age, inclusive, and will receive a lower, middle or higher dose
      of study agent. Subjects in Group 4 will be between 6 and 55 years of age, inclusive, and
      will receive the maximum tolerated dose identified in Groups 1, 2 and 3.

      Safety will be monitored by evaluation of ocular and non ocular adverse events and
      hematology and clinical chemistry parameters. Efficacy parameters will include visual
      acuity, light discomfort testing, color vision, static visual field, ERG, adaptive optics
      retinal imaging and OCT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants experiencing grade 3 or greater adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in best corrected visual acuity compared to pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light aversion</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in light discomfort testing compared to pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in color vision testing compared to pre-treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Achromatopsia</condition>
  <arm_group>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGTC-402 will be administered at the lowest of three planned dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGTC-402 will be administered at the middle of three planned dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGTC-402 will be administered at the highest of three planned dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maximum tolerated dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGTC-402 will be administered at the maximum tolerated dose identified from Groups 1, 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AGTC-402</intervention_name>
    <description>AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.</description>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_label>Higher dose</arm_group_label>
    <arm_group_label>Maximum tolerated dose</arm_group_label>
    <other_name>rAAV2tYF-PR1.7-hCNGA3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Retinal disease consistent with a diagnosis of achromatopsia and documented mutations
             in both alleles of the CNGA3 gene;

          2. Between 18 and 55 years of age, inclusive, for Groups 1, 2 and 3 and between 6 and 55
             years of age, inclusive, for Group 4;

          3. Able to perform tests of visual and retinal function;

          4. Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent
             20/80) based on the average of two examinations at the baseline visit;

          5. Acceptable laboratory parameters;

          6. For females of childbearing potential: A negative pregnancy test within 2 days before
             administration of study agent.

        Exclusion Criteria:

          1. Presence of myopia which, in the opinion of Investigator, may create increased
             surgical risk for the subject in the study eye;

          2. Evidence of degenerative myopia in the study eye;

          3. Pre-existing eye conditions that would contribute to vision loss in either eye or
             increase the risk of subretinal injection in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Goldstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Genetics Technologies Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Dolgin, PharmD</last_name>
    <phone>617-843-5781</phone>
    <email>jdolgin@agtc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicki Bell, PhD</last_name>
    <phone>386-462-2204</phone>
    <phone_ext>7136</phone_ext>
    <email>nbell@agtc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VitreoRetinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.agtc.com</url>
    <description>AGTC website</description>
  </link>
  <reference>
    <citation>Banin E, Gootwine E, Obolensky A, Ezra-Elia R, Ejzenberg A, Zelinger L, Honig H, Rosov A, Yamin E, Sharon D, Averbukh E, Hauswirth WW, Ofri R. Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia. Mol Ther. 2015 Sep;23(9):1423-33. doi: 10.1038/mt.2015.114. Epub 2015 Jun 19.</citation>
    <PMID>26087757</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>October 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Color vision deficiency</keyword>
  <keyword>Color vision defects</keyword>
  <keyword>Vision disorders</keyword>
  <keyword>Sensation disorders</keyword>
  <keyword>Neurologic manifestations</keyword>
  <keyword>Nervous system diseases</keyword>
  <keyword>Eye diseases</keyword>
  <keyword>Signs and symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Color Vision Defects</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
